Table 2.
Observed responses in central composite design for optimization of ITZ-loaded invasomes formulation and summary of results of regression analysis for responses Y1, Y2 and Y3 for fitting to quadratic model
| Formulations | Independent variables | Dependent variables | |||
|---|---|---|---|---|---|
| X1 | X2 | Y1 | Y2 | Y3 | |
| F1 | 23.43 | 1.00 | 46.51 ± 3.01 | 41.43 ± 2.85 | 51.12 ± 4.43 |
| F2 | 80.00 | 1.00 | 163.41 ± 9.56 | 78.23 ± 7.86 | 69.22 ± 5.31 |
| F3 | 80.00 | 1.71 | 189.23 ± 9.31 | 66.15 ± 6.31 | 74.15 ± 5.02 |
| F4 | 80.00 | 1.00 | 159.20 ± 8.61 | 76.73 ± 2.01 | 68.34 ± 3.41 |
| F5 | 120.00 | 0.50 | 201.02 ± 8.43 | 68.35 ± 2.43 | 47.24 ± 3.10 |
| F6 | 80.00 | 1.00 | 176.80 ± 6.03 | 83.21 ± 4.11 | 75.22 ± 5.03 |
| F7 | 40.00 | 1.50 | 87.18 ± 5.10 | 58.42 ± 3.32 | 81.42 ± 6.35 |
| F8 | 40.00 | 0.50 | 49.34 ± 2.01 | 53.21 ± 6.20 | 50.31 ± 6.21 |
| F9 | 136.57 | 1.00 | 196.41 ± 7.12 | 86.23 ± 3.16 | 42.19 ± 2.04 |
| F10 | 80.00 | 1.00 | 158.27 ± 8.11 | 79.02 ± 4.32 | 70.26 ± 3.17 |
| F11 | 80.00 | 0.29 | 121.12 ± 8.18 | 64.73 ± 4.01 | 52.12 ± 3.26 |
| F12 | 120.00 | 1.50 | 214.31 ± 7.25 | 85.15 ± 7.31 | 52.41 ± 2.23 |
| F13 | 80.00 | 1.00 | 164.12 ± 6.17 | 81.42 ± 5.14 | 71.52 ± 5.16 |
| Quadratic model | R2 | Adjusted R2 | Predicted R2 | SD | %CV |
|---|---|---|---|---|---|
| Y1 | 0.9723 | 0.9525 | 0.8355 | 12.15 | 8.20 |
| Y2 | 0.9381 | 0.8938 | 0.6252 | 4.47 | 6.30 |
| Y3 | 0.9517 | 0.9172 | 0.7365 | 3.72 | 6.00 |
X1 phospholipid (mg), X2 valencene (%), Y1 vesicles size (nm), Y2 EE (%), Y3 In vitro release (%), CV coefficient of variation, EE entrapment efficiency, ITZ itraconazole, SD standard deviation